Nicholas Restifo
Chief Medical Officer Medici Therapeutics
Seminars
Wednesday 18th November 2026
Advancing TIL Therapy Through Neoantigen-Guided Selection of Tumor- Reactive T-Cells
12:00 pm
- Leveraging patient-specific neoantigens to identify and enrich functional tumorreactive T-cells
- Overcoming low frequencies of tumor-reactive lymphocytes in non-melanoma solid tumors
- Establishing a framework for next-generation, precision TIL manufacturing
